Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations

Nature

Volumn 513, Issue 7518, 2014, Pages 418-421

  Fridman, Ofer ^a   Goldberg, Amir ^a   Ronin, Irine ^a   Shoresh, Noam ^b   Balaban, Nathalie Q ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT;

ALLELE; ANTIBIOTICS; GROWTH RESPONSE; MICROBIAL COMMUNITY; OPTIMIZATION; PHENOTYPIC PLASTICITY; POPULATION GENETICS; TOLERANCE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; GENE SEQUENCE; LAG TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TIME; TREATMENT DURATION; ALLELE; CYTOLOGY; DRUG EFFECT; DRUG TOLERANCE; ESCHERICHIA COLI; GROWTH, DEVELOPMENT AND AGING;

BACTERIA (MICROORGANISMS);

ALLELES; AMPICILLIN; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG TOLERANCE; ESCHERICHIA COLI; PHENOTYPE; TIME FACTORS;

EID: 84907879368     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13469     Document Type: Article

References (30)

1. Bush, K. et al. Tackling antibiotic resistance. Nature Rev. Microbiol. 9, 894-896 (2011).
2. Balaban, N., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a phenotypic switch. Science 305, 1622-1625 (2004).
3. Collignon, P. Antibiotic resistance. Med. J. Aust. 177, 325-329 (2002).
4. Spellberg, B., Powers, J., Brass, E., Miller, L. & Edwards, J. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004).
5. Fauvart, M., De Groote, V. & Michiels, J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J. Med. Microbiol. 60, 699-709 (2011).
6. Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357-372 (2010).
7. Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nature Genet. 44, 101-105 (2012).
8. Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathogens 7 (2011).
9. Lee, H., Molla, M., Cantor, C. & Collins, J. Bacterial charity work leads to population-wide resistance. Nature 467, 82-85 (2010).
10. Olsson, O., Bergström, S., Lindberg, F. & Normark, S. ampC β-lactamase hyperproduction in Escherichia coli: natural ampicillin resistance generated by horizontal chromosomal DNA transfer from Shigella. Proc. Natl Acad. Sci. USA 80, 7556-7560 (1983).
11. Gilbert, P., Collier, P. & Brown, M. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob. Agents Chemother. 34, 1865-1868 (1990).
12. Baranyi, J. Stochastic modelling of bacterial lag phase. Int. J. Food Microbiol. 73, 203-206 (2002).
13. Gefen, O. & Balaban, N. The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol. Rev. 33, 704-717 (2009).
14. Tuomanen, E., Cozens, R., Tosch, W., Zak, O. & Tomasz, A. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132, 1297-1304 (1986).
15. Wolfson, J., Hooper, D., McHugh, G., Bozza, M. & Swartz, M. Mutants of Escherichia coli K-12 exhibiting reduced killing by both quinolone and β-lactam antimicrobial agents. Antimicrob. Agents Chemother. 34, 1938-1943 (1990).
16. Levin-Reisman, I. et al. Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes. Nature Methods 7, 737-739 (2010).
17. Goecks, J., Nekrutenko, A., Taylor, J. & Galaxy, T. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11, R86 (2010).
18. Black, D., Kelly, A., Mardis, M. & Moyed, H. Structure and organization of hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. J. Bacteriol. 173, 5732-5739 (1991).
19. Gerdes, K. & Maisonneuve, E. Bacterial persistence and toxin-antitoxin loci. Annu. Rev. Microbiol. 66, 103-123 (2012).
20. Girgis, H., Harris, K. & Tavazoie, S. Large mutational target size for rapid emergence of bacterial persistence. Proc. Natl Acad. Sci. USA 109, 12740-12745 (2012).
21. Kaspy, I. et al. HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. Nature Commun. 4, 3001 (2013).
22. Germain, E., Castro-Roa, D., Zenkin, N. & Gerdes, K. Molecular mechanism of bacterial persistence by HipA. Mol. Cell 52, 248-254 (2013).
23. Rotem, E. et al. Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence. Proc. Natl Acad. Sci. USA 107, 12541-12546 (2010).
24. Oxman, E., Alon, U. & Dekel, E. Defined order of evolutionary adaptations: experimental evidence. Evolution 62, 1547-1554 (2008).
25. Beaumont, H., Gallie, J., Kost, C., Ferguson, G. & Rainey, P. Experimental evolution of bet hedging. Nature 462, 90-93 (2009).
26. Kussell, E., Kishony, R., Balaban, N. & Leibler, S. Bacterial persistence: a model of survival in changing environments. Genetics 169, 1807-1814 (2005).
27. Mitchell, A. et al. Adaptive prediction of environmental changes by microorganisms. Nature 460, 220-224 (2009).
28. Nahata, M., Vashi, V., Swanson, R., Messig, M. & Chung, M. Pharmacokinetics of ampicillin and sulbactamin pediatric patients. Antimicrob. Agents Chemother. 43, 1225-1229 (1999).
29. Cohen, N., Lobritz, M. & Collins, J. Microbial persistence and the road to drug resistance. Cell Host Microbe 13, 632-642 (2013).
30. Barrick, J. et al. Genome evolution and adaptation in a long-term experiment with Escherichia coli. Nature 461, 1243-1247 (2009).